Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $30.80

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

EADV26: Key late-stage readouts from the conference

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027

After two doses, patients’ eczema responses kept improving for eight weeks.

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN)

Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?

Evommune Halts Atopic Dermatitis Program Following Trial Failure

This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On

$EVMN stock is down 15% today. Here's what we see in our data.

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Why Is EVMN Stock Down 13% After-Hours?